Journal
TOXINS
Volume 14, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/toxins14030177
Keywords
uremic toxins; albumin; cell transporters
Categories
Funding
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil [001]
- Sao Paulo Research Foundation (FAPESP) [2019/11077-0]
Ask authors/readers for more resources
Uremic toxins are molecules that accumulate in the body due to chronic kidney disease (CKD), and are associated with kidney dysfunction and comorbidity development. Drugs may interact with protein-bound uremic toxins (PBUTs) and cell membrane transporters, affecting toxin levels and elimination. This review explores the interaction mechanisms between uremic toxins, albumin, and membrane transporters in relation to clinical drug use.
Uremic toxins are a heterogeneous group of molecules that accumulate in the body due to the progression of chronic kidney disease (CKD). These toxins are associated with kidney dysfunction and the development of comorbidities in patients with CKD, being only partially eliminated by dialysis therapies. Importantly, drugs used in clinical treatments may affect the levels of uremic toxins, their tissue disposition, and even their elimination through the interaction of both with proteins such as albumin and cell membrane transporters. In this context, protein-bound uremic toxins (PBUTs) are highlighted for their high affinity for albumin, the most abundant serum protein with multiple binding sites and an ability to interact with drugs. Membrane transporters mediate the cellular influx and efflux of various uremic toxins, which may also compete with drugs as substrates, and both may alter transporter activity or expression. Therefore, this review explores the interaction mechanisms between uremic toxins and albumin, as well as membrane transporters, considering their potential relationship with drugs used in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available